These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 14871801)

  • 1. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.
    Ekholm-Reed S; Spruck CH; Sangfelt O; van Drogen F; Mueller-Holzner E; Widschwendter M; Zetterberg A; Reed SI
    Cancer Res; 2004 Feb; 64(3):795-800. PubMed ID: 14871801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.
    Cassia R; Moreno-Bueno G; Rodríguez-Perales S; Hardisson D; Cigudosa JC; Palacios J
    J Pathol; 2003 Dec; 201(4):589-95. PubMed ID: 14648662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.
    Kwak EL; Moberg KH; Wahrer DC; Quinn JE; Gilmore PM; Graham CA; Hariharan IK; Harkin DP; Haber DA; Bell DW
    Gynecol Oncol; 2005 Jul; 98(1):124-8. PubMed ID: 15913747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.
    Yu JC; Ding SL; Chang CH; Kuo SH; Chen ST; Hsu GC; Hsu HM; Hou MF; Jung LY; Cheng CW; Wu PE; Shen CY
    Carcinogenesis; 2009 Sep; 30(9):1562-70. PubMed ID: 19587092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
    Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
    Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.
    Lerner M; Lundgren J; Akhoondi S; Jahn A; Ng HF; Akbari Moqadam F; Oude Vrielink JA; Agami R; Den Boer ML; Grandér D; Sangfelt O
    Cell Cycle; 2011 Jul; 10(13):2172-83. PubMed ID: 21597324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hCDC4 gene mutations in endometrial cancer.
    Spruck CH; Strohmaier H; Sangfelt O; Müller HM; Hubalek M; Müller-Holzner E; Marth C; Widschwendter M; Reed SI
    Cancer Res; 2002 Aug; 62(16):4535-9. PubMed ID: 12183400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.
    Strohmaier H; Spruck CH; Kaiser P; Won KA; Sangfelt O; Reed SI
    Nature; 2001 Sep; 413(6853):316-22. PubMed ID: 11565034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
    Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
    Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
    Tu K; Zheng X; Zhou Z; Li C; Zhang J; Gao J; Yao Y; Liu Q
    PLoS One; 2013; 8(7):e68574. PubMed ID: 23840897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Fbxw7/hCdc4 tumor suppressor in human cancer.
    Tan Y; Sangfelt O; Spruck C
    Cancer Lett; 2008 Nov; 271(1):1-12. PubMed ID: 18541364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells.
    Willmarth NE; Albertson DG; Ethier SP
    Breast Cancer Res; 2004; 6(5):R531-9. PubMed ID: 15318934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclins in breast cancer: too much of a good thing.
    Enders GH
    Breast Cancer Res; 2002; 4(4):145-7. PubMed ID: 12100739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of hCDC4 can cause chromosomal instability.
    Rajagopalan H; Jallepalli PV; Rago C; Velculescu VE; Kinzler KW; Vogelstein B; Lengauer C
    Nature; 2004 Mar; 428(6978):77-81. PubMed ID: 14999283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms.
    van Drogen F; Sangfelt O; Malyukova A; Matskova L; Yeh E; Means AR; Reed SI
    Mol Cell; 2006 Jul; 23(1):37-48. PubMed ID: 16818231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hCDC4 variation in osteosarcoma.
    Yan T; Wunder JS; Gokgoz N; Seto KK; Bell RS; Andrulis IL
    Cancer Genet Cytogenet; 2006 Sep; 169(2):138-42. PubMed ID: 16938571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of the hCDC4 gene in gastric carcinomas.
    Lee JW; Soung YH; Kim HJ; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
    Eur J Cancer; 2006 Sep; 42(14):2369-73. PubMed ID: 16824748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.
    Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grandér D; Lendahl U; Sangfelt O
    Cancer Res; 2007 Jun; 67(12):5611-6. PubMed ID: 17575125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.
    Klotz K; Cepeda D; Tan Y; Sun D; Sangfelt O; Spruck C
    Exp Cell Res; 2009 Jul; 315(11):1832-9. PubMed ID: 19084516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.
    Caldon CE; Sergio CM; Sutherland RL; Musgrove EA
    Cell Cycle; 2013 Feb; 12(4):596-605. PubMed ID: 23324394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.